ONKOLOGIK BEMORLARDA KIMYOTERAPIYADAN KEYINGI KO'NGIL AYNISHI VA QUSISHNI BARTARAF ETISHNING ZAMONAVIY SXEMALARI

Authors

  • Ismoilova Gulruh Ulugʻbek qizi Onkologiya va tibbiy radiologiya yo’nalishi 1-kurs ordinatori CAMU

Keywords:

kimyoterapiya, ko‘ngil aynishi, qusish, CINV, antiemetik terapiya, 5-NT3 antagonistlari, NK1 antagonistlari, olanzapin, deksametazon, onkologik bemor.

Abstract

Kimyoterapiya bilan bog‘liq ko‘ngil aynishi va qusish (Chemotherapy-Induced Nausea and Vomiting — CINV) onkologik bemorlarning hayot sifatini sezilarli darajada pasaytiruvchi eng muhim nojo‘ya ta'sirlardan biridir. So‘nggi yillarda antiemetik terapiya bo‘yicha xalqaro tavsiyalar yangilanib, 5-NT3 retseptor antagonistlari, NK1 retseptor antagonistlari, deksametazon hamda olanzapin asosidagi kombinatsiyalangan davolash sxemalari keng qo‘llanila boshlandi. Ushbu maqolada kimyoterapiyadan keyingi ko‘ngil aynishi va qusishning rivojlanish mexanizmlari, xavf omillari, zamonaviy profilaktika va davolash sxemalari hamda ularning klinik samaradorligi tahlil qilinadi. Tadqiqot natijalari zamonaviy antiemetik protokollarni individual xavf omillarini hisobga olgan holda qo‘llash CINV nazoratini yaxshilashi, bemorlarning davolanishga sodiqligini oshirishi va hayot sifatini sezilarli darajada yaxshilashini ko‘rsatadi.

References

Aapro M, Molassiotis A, Dicato M. Supportive care in cancer: Current perspectives. Ann Oncol. 2021;32:1120–1132.

Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: Clinical practice guideline update. J Clin Oncol. 2020;38:2782–2797.

Bloechl-Daum B, Deuson RR, Mavros P, et al. Delayed nausea and vomiting continue to reduce quality of life after chemotherapy. Support Care Cancer. 2020;28:3645–3653.

Cohen L, de Moor CA, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting: Incidence and impact. Cancer. 2021;127:135–145.

European Society for Medical Oncology (ESMO). Clinical Practice Guidelines: Antiemetic therapy. 2024.

Gralla RJ, Bosnjak SM, Hontsa A, et al. Practical management of CINV in routine oncology practice. Oncologist. 2022;27:e563–e574.

Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and vomiting after modern antiemetics. Cancer. 2021;127:146–154.

Herrstedt J, Celio L, Hesketh PJ, et al. 2023 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following high-emetic-risk antineoplastic agents. Support Care Cancer. 2024;32:47.

Herrstedt J, Roila F, Warr D, et al. Antiemetic therapy in oncology: Recent developments. Support Care Cancer. 2023;31:456–468.

Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020;38(24):2782–2797.

Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358:2482–2494.

Hesketh PJ. Prevention and treatment of chemotherapy-induced nausea and vomiting. UpToDate. 2025.

Jordan K, Aapro M, Kaasa S. Supportive care in cancer: Recent advances. ESMO Open. 2022;7:100420.

Jordan K, Chan A, Gralla RJ, et al. 2023 MASCC/ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. Support Care Cancer. 2024;32:44.

Jordan K, Gralla R, Jahn F, Molassiotis A. International antiemetic guidelines: 2023 update. Support Care Cancer. 2024.

Molassiotis A, Chan A, Yam BM, et al. Evidence-based management of chemotherapy-induced nausea and vomiting. Support Care Cancer. 2021;29:525–538.

Molassiotis A, Chan A. Recent advances in supportive oncology care. Lancet Oncol. 2023;24:e475–e486.

National Cancer Institute. PDQ® Supportive and Palliative Care: Nausea and Vomiting Related to Cancer Treatment. Bethesda; 2024.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 2025.

Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2022;386:2305–2315.

Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. JAMA Oncol. 2020;6(7):e200608.

Navari RM. Management of chemotherapy-induced nausea and vomiting: Focus on newer agents and new uses for older agents. Drugs. 2021;81(1):1–20.

Navari RM. Olanzapine for prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2022;922:174890.

Navari RM. Pharmacologic management of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2023;24:1259–1271.

Olver I, Aapro M, Jordan K, et al. 2023 updated MASCC/ESMO consensus recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential. Support Care Cancer. 2024;32:46.

Rapoport BL, Navari RM, Molassiotis A, et al. 2023 updated MASCC/ESMO consensus recommendations: Multiple-day chemotherapy, breakthrough and refractory CINV. Support Care Cancer. 2024.

Razvi Y, Chan S, McFarlane T, et al. ASCO, NCCN, MASCC/ESMO: A comparison of antiemetic guidelines for chemotherapy-induced nausea and vomiting. Support Care Cancer. 2019;27:87–95.

Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC/ESMO antiemetic guideline update. Ann Oncol. 2016;27(Suppl 5):v119–v133.

Ruhlmann CH, Jordan K, Jahn F, et al. 2023 updated MASCC/ESMO consensus recommendations: Prevention of radiotherapy- and chemoradiotherapy-induced nausea and vomiting. Support Care Cancer. 2024;32:26.

Scotté F, Schwartzberg L, Iihara H, et al. 2023 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetic-risk antineoplastic agents. Support Care Cancer. 2024;32:45.

Downloads

Published

2026-07-08

How to Cite

Ismoilova Gulruh Ulugʻbek qizi. (2026). ONKOLOGIK BEMORLARDA KIMYOTERAPIYADAN KEYINGI KO’NGIL AYNISHI VA QUSISHNI BARTARAF ETISHNING ZAMONAVIY SXEMALARI. IQRO , 22(02), 148–151. Retrieved from https://wordlyknowledge.uz/index.php/iqro/article/view/8626